Cell Reports (Aug 2024)

Activated dormant stem cells recover spermatogenesis in chemoradiotherapy-induced infertility

  • Shu-Hua Yang,
  • Yi-Zhe Zeng,
  • Xi-Zheng Jia,
  • Yun-Wen Gu,
  • Christopher Wood,
  • Ri-Sheng Yang,
  • Jin-Shu Yang,
  • Wei-Jun Yang

Journal volume & issue
Vol. 43, no. 8
p. 114582

Abstract

Read online

Summary: Male infertility is a recognized side effect of chemoradiotherapy. Extant spermatogonial stem cells (SSCs) may act as originators for any subsequent recovery. However, which type of SSCs, the mechanism by which they survive and resist toxicity, and how they act to restart spermatogenesis remain largely unknown. Here, we identify a small population of Set domain-containing protein 4 (Setd4)-expressing SSCs that occur in a relatively dormant state in the mouse seminiferous tubule. Extant beyond high-dose chemoradiotherapy, these cells then activate to recover spermatogenesis. Recovery fails when Setd4+ SSCs are deleted. Confirmed to be of fetal origin, these Setd4+ SSCs are shown to facilitate early testicular development and also contribute to steady-state spermatogenesis in adulthood. Upon activation, chromatin remodeling increases their genome-wide accessibility, enabling Notch1 and Aurora activation with corresponding silencing of p21 and p53. Here, Setd4+ SSCs are presented as the originators of both testicular development and spermatogenesis recovery in chemoradiotherapy-induced infertility.

Keywords